Latest Eosinophil granulocyte Stories
UC San Francisco Study Examines Role of Immune Cell in Triggering Muscle Regrowth UC San Francisco scientists have discovered that muscle repair requires the action of two types of cells better known for causing inflammation and forming fat. The finding in mice, published in the April 11 issue of Cell, showed that a well-known immune cell called the eosinophil [ee-oh-SIN-oh-fil] carries out the beneficial role in two ways – by clearing out cellular debris from damaged tissue and...
California Institute of Technology White blood cells, or leukocytes, are the immune system's warriors. So when an infection or disease attacks the body, the system typically responds by sending more white blood cells into the fray. This means that checking the number of these cells is a relatively easy way to detect and monitor such conditions. Currently, most white blood cell counts are performed with large-scale equipment in central clinical laboratories. If a physician collects blood...
A simple new test, in which the patient swallows a string, can monitor treatment of eosinophilic esophagitis as effectively as an invasive, expensive and uncomfortable procedure that risks complications, particularly in children. Researchers from the University of Illinois at Chicago College of Medicine, working in collaboration with clinician-investigators at the University of Colorado Denver/Children's Hospital Colorado and Lurie Children's Hospital in Chicago, reported their findings in...
SAN DIEGO, Aug. 13, 2012 /PRNewswire/ -- Meritage Pharma, Inc. announced today that it has initiated a Phase 2 clinical trial to evaluate oral budesonide suspension (OBS) for the treatment of adolescents and young adults with eosinophilic esophagitis (EoE), an allergic inflammatory condition of the esophagus. EoE is a chronic disease characterized by symptoms related to esophageal dysfunction and eosinophil-predominant inflammation. The trial is being conducted at multiple U.S....
CINCINNATI, March 28, 2012 /PRNewswire-USNewswire/ -- Researchers have taken a critical step in understanding how allergic reactions occur after identifying a genetic signature for regulation of a key immune hormone, interleukin (IL-13). (Logo: http://photos.prnewswire.com/prnh/20110406/MM79025LOGO) Scientists from Cincinnati Children's Hospital Medical Center say the finding opens the potential for new molecular targets to treat allergic disease. They report on March 28 in Mucosal...
CINCINNATI, March 9, 2012 /PRNewswire-USNewswire/ -- Researchers have identified a genetic signature for a severe, often painful food allergy - eosinophilic esophagitis - that could lead to improved diagnosis and treatment for children unable to eat a wide variety of foods. (Logo: http://photos.prnewswire.com/prnh/20110406/MM79025LOGO) The scientists, from Cincinnati Children's Hospital Medical Center, report in the Journal of Allergy and Clinical Immunology that they have...
A large percentage of patients with mild-to-moderate asthma have persistently non-eosinophilic disease which may not respond to currently available anti-inflammatory treatments, according to a new study. In a cross-sectional study of 995 asthmatic subjects enrolled in nine clinical trials conducted by the NHLBI's Asthma Clinical Research Network, sputum eosinophilia (≥2% eosinophils) was found in only 36% of asthmatics not using an inhaled corticosteroid (ICS) and 17% of those using an...
SAN DIEGO, Oct. 17, 2011 /PRNewswire/ -- Panmira Pharmaceuticals, LLC, today announced the appointment of Hari Kumar, PhD, as chief executive officer. Until recently, Dr. Kumar served as chief business officer of Amira Pharmaceuticals Inc. and led the transaction with Bristol-Myers Squibb Inc. for the sale of Amira's fibrosis program. Dr. Kumar and his team will oversee efforts on Panmira's inflammation portfolio, which features a best-in-class CRTH2 program. The lead candidate, AM211,...
SRxA Strategic Pharmaceutical Advisors, LLC, a leading healthcare consulting, marketing and education firm, is pleased to announce that it has entered into an agreement with the Executive Directors and organizers of the International Eosinophil Society, Inc. (IES) to become the exclusive provider of rapid dissemination post-symposium e-Newsletter. Washington, DC (PRWEB) June 04, 2011 SRxA Strategic Pharmaceutical Advisors, LLC, a leading healthcare consulting, marketing and education...
CHICAGO, May 10, 2011 /PRNewswire/ -- Meritage Pharma, Inc. announced today its proprietary oral budesonide suspension (OBS) met the primary endpoint of reduction of esophageal eosinophilia and symptoms in a Phase 2b dose-ranging clinical trial in pediatric patients with eosinophilic esophagitis (EoE), an allergic inflammatory condition of the esophagus. Results from the Pediatric Eosinophilic Esophagitis Research (PEER) study were presented by principal investigators at Digestive Disease...
